Vimian Group AB (VIMIAN) AI Stock Analysis

• Market Cap: €22.70B
• Dividend Yield: N/A
• Average Volume (3M): 413.37K
• Price to Earnings (P/E): 103.3
• Beta (1Y): 0.42
• Revenue Growth: 16.00%
• EPS Growth: 126.41%
• Country: SE
• Employees: 1,200
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.20
• Shares Outstanding: 517,895,100
• 10 Day Avg. Volume: 809,099
• 30 Day Avg. Volume: 413,371
• PEG Ratio: N/A
• Price to Book (P/B): 2.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 35.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €45.51
• Price Target Upside: 3.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 68 Neutral
• Price Target: kr50.00 ▲(14.05%Upside)

Vimian Group AB demonstrates strong financial performance with solid revenue and profit growth, efficient operations, and robust cash flow generation. However, the technical indicators suggest potential overbought conditions, and the high P/E ratio raises concerns about overvaluation. The absence of dividend yield also detracts from its investment appeal.

Positive Factors

Market Listing

Vimian's approval to list on the Nasdaq Stockholm Main Market in the Large Cap segment is expected to improve share liquidity and elevate the company's profile.

Profitability

Vimian's profitability exceeded expectations with a significant increase in net sales and strong organic growth across key segments.

Negative Factors

MedTech Performance

MedTech experienced a decline in organic growth due to the final phase-out of the AOP and challenges in the US surgery market.

Profit Margins

The adjusted EBITA margin decreased, reflecting the effects of R&D capitalization, a write-off in Specialty Pharma, and increased investments in marketing and sales.

Vimian Group AB Business Overview & Revenue Model

Company Description

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

Vimian Group AB generates revenue through its diversified operations across multiple sectors in the animal health industry. Its revenue streams include the sale of specialty pharmaceuticals that address specific health issues in animals, diagnostics products that aid in the identification of diseases, and advanced technology solutions that improve veterinary practice efficiency. Additionally, Vimian provides veterinary services that offer direct support and expertise to animal health practitioners. The company benefits from strategic partnerships and collaborations with veterinary clinics, research institutions, and other healthcare entities that enhance its market presence and drive sales growth.

Vimian Group AB Financial Statement Overview

Summary

Vimian Group AB shows a robust financial performance with consistent revenue and profit growth. The company maintains a healthy balance sheet with moderate leverage and strong equity support. Cash flow generation is strong, enhancing the company's liquidity position.

Income Statement

The company has demonstrated consistent revenue growth over the years, with a significant increase in total revenue from 2020 to TTM 2025. Gross Profit Margin is strong, and there is a notable improvement in Net Profit Margin over the periods, indicating enhanced profitability. The EBIT and EBITDA margins are also favorable, reflecting efficient operations.

Balance Sheet

The balance sheet shows a solid equity base with a consistent increase in stockholders' equity over time. The Debt-to-Equity Ratio is moderate, suggesting manageable leverage. The Equity Ratio indicates a stable financial structure, although there has been a gradual increase in total debt.

Cash Flow

The cash flow statement reflects strong Free Cash Flow growth, particularly from 2023 to TTM 2025, demonstrating effective cash management. Operating Cash Flow has also improved significantly, supporting the company's ability to generate cash relative to net income.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
391.04M	374.80M	331.73M	281.31M	173.35M	137.75M
	Gross Profit
269.89M	258.30M	229.43M	193.99M	122.85M	95.52M
	EBIT
51.41M	49.20M	41.27M	39.36M	21.60M	74.80M
	EBITDA
87.04M	82.80M	69.19M	66.32M	40.98M	65.16M
	Net Income Common Stockholders
19.25M	18.50M	9.84M	-7.20M	6.59M	52.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.50M	64.80M	37.50M	42.19M	55.11M	29.66M
	Total Assets
973.68M	1.11B	973.68M	923.56M	640.72M	456.29M
	Total Debt
313.80M	233.60M	313.80M	220.96M	180.37M	85.91M
	Net Debt
276.30M	168.80M	276.30M	178.76M	125.25M	56.24M
	Total Liabilities
446.97M	403.30M	446.97M	442.06M	282.08M	182.05M
	Stockholders Equity
526.37M	699.90M	526.37M	481.81M	357.41M	224.02M
Cash Flow		Free Cash Flow
51.92M	43.90M	-43.48M	15.01M	4.52M	-793.00K
	Operating Cash Flow
64.07M	58.10M	-28.58M	25.31M	16.01M	4.80M
	Investing Cash Flow
-82.54M	-76.00M	-77.68M	-188.53M	-115.00M	-105.24M
	Financing Cash Flow
39.69M	44.80M	100.55M	150.23M	123.94M	118.57M

Vimian Group AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Positive. The current price of 43.84 is above the 20-day moving average (MA) of 41.41, above the 50-day MA of 39.94, and above the 200-day MA of 41.48, indicating a bullish trend. The MACD of 1.27 indicates Negative momentum. The RSI at 58.77 is Neutral, neither overbought nor oversold. The STOCH value of 57.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VIMIAN.

Vimian Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIMIAN	68 Neutral	€22.70B	103.32	3.18%	―	16.00%	126.41%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
0O5H		kr19.09B	80.29	2.43%	4.84%	―	―
0YAY		kr20.87B	41.97	3.79%	0.69%	―	―
ADDLF		$2.48B	85.81	5.83%	0.35%	―	―
BOEUF		$1.84B	160.21	18.01%	―	―	―
PGO0		€3.76M	―	-139.61%	―	―	―

Vimian Group AB Corporate Events

Vimian Group AB Adopts New Incentive Programs and Remuneration Guidelines

Vimian Group AB held an Extraordinary General Meeting on June 11, 2025, where shareholders approved several key resolutions. These included adopting new Articles of Association to introduce reclassifiable and redeemable share classes for the company’s incentive program, implementing a long-term performance-based share program for employees and consultants, and updating remuneration guidelines to allow for incentive programs to be adopted by both Annual and Extraordinary General Meetings. These changes are expected to enhance Vimian’s operational flexibility and align with local laws and practices, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Successfully Issues EUR 150 Million in Bonds

Vimian Group AB has successfully issued EUR 150 million in senior unsecured bonds, significantly oversubscribed, with plans to list them on Nasdaq Stockholm. This move reflects strong investor confidence and is expected to enhance Vimian’s financial flexibility, supporting its growth in the animal health sector.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Plans EUR 125 Million Bond Issuance

Vimian Group AB is considering issuing a senior unsecured bond to raise EUR 125 million, with a potential framework of EUR 250 million, subject to market conditions. The proceeds will be used to refinance existing debt and support corporate activities, including acquisitions and investments, potentially impacting its financial strategy and market positioning.